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Abstract An oligonucleotide conjugate bearing a chemical
construct mimicking the catalytic center of ribonuclease A has
been designed and studied. The conjugate efficiently cleaves yeast
tRNAPhe at a single site adjacent to the target complementary
sequence. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In the last years a great progress has been made in develop-
ment of oligonucleotide-based therapeutics targeted to speci¢c
RNAs of infectious agents and cellular RNAs encoding dis-
ease-causing products [1]. The currently used phosphodiester
oligonucleotides and phosphorothioate oligonucleotide ana-
logs trigger cleavage of the target RNAs by cellular enzyme
RNase H that attacks the RNA strands in duplexes formed by
RNA and DNA. This catalytic reaction provides the basis of
e⁄ciency of these oligonucleotides in vivo. Binding of other
known oligonucleotide analogs to RNA yields complexes, that
are not substrates for RNase H and generally these analogs
cannot e⁄ciently arrest functions of target RNAs except when
they interfere with speci¢c protein^mRNA interactions [2].
Therefore some alternative approaches for improving anti-
sense e⁄ciency of oligonucleotide analogs are needed.
The e⁄cacy of antisense oligonucleotides can be increased
by conjugating them to reactive groups capable of irreversible
damaging nucleic acids [3]. Of the reactive groups, particularly
promising are those catalyzing hydrolytic cleavage of RNA,
because they do not a¡ect biopolymers other than RNA and
should be highly e⁄cient due to their catalytic nature [4^6].
Groups catalyzing RNA hydrolysis can be designed by mim-
icking active centers of ribonucleases. We have demonstrated
a possibility to cleave RNA with small molecules containing
imidazole residues conjugated by linkers of variable length
and £exibility to intercalating dyes [7] and to cationic mole-
cules [8,9]. Conjugation of imidazole-bearing constructs to
oligonucleotides was shown to yield molecules cleaving
RNA at speci¢c target sequences [10^12]. However e⁄cacy
of the described RNA-cleaving oligonucleotide conjugates is
rather poor. Reasonable cleavage can be achieved only after
long incubation of target RNAs with conjugates in conditions
inconsistent with biological experiments.
We have attempted to design improved RNase mimics and
optimize the linker structure connecting them to oligonucleo-
tide. We have designed an oligonucleotide conjugate that
causes e⁄cient cleavage of speci¢c target sequence in RNA
in physiological conditions.
2. Materials and methods
All bu¡er solutions used in the experiments were prepared using
Milli-Q water, contained 1 mM EDTA and were ¢ltered through
membrane ¢lters with 0.2 Wm pores.
[Q-32P]ATP was from Biosan Co., Russia. Enzymes and chemicals
used for end-labeling of RNA and the electrophoretic analysis were as
described in [13]. Yeast tRNAPhe isolated by established procedures
was a generous gift from Dr. G. Keith (Institute de Biologie Molecu-
laire et Cellulaire de CNRS, Strasbourg, France).
3P-[32P]tRNAPhe was obtained according to published protocols
[14]. 15 Wl reaction mixture contained 50 mM HEPES^KOH, pH
7.5; 10 mM MgCl2 ; 10% DMSO; 0.1 mM ATP; 2 mM DTE; 100
Wg/ml BSA; 160 pmol of tRNAPhe ; 200 WCi 5P-[32P]pCp and 20 units
of T4 RNA ligase. The reaction was performed at 4‡C overnight.
After labeling, the tRNA was puri¢ed by electrophoresis in 12% poly-
acrylamide^8 M urea gel. The labeled RNA was eluted from the gel
by 0.5 M ammonium acetate containing 1.0 mM EDTA and 0.1%
SDS. After ethanol precipitation, the tRNA was dissolved in water
and stored at 320‡C. The speci¢c activity of the obtained
[32P]tRNAPhe was 5U105 cpm/pmol.
2.1. Synthesis of the oligonucleotide conjugated to RNA-cleaving
bis-imidazole construct (2B-R) (Scheme 1)
Oligonucleotide GATCGAACACAGGACCT (further in the text
2B) was synthesized by using the phosphotriester method [15]. The
synthesis of RNA cleaving histamine-L-alanyl-histidyl-capromayl-g-
maleimide (compound 2 in Scheme 1) will be published elsewhere.
The 9-aminomethylanthracene was attached to the terminal 5P-phos-
phate of oligonucleotide that had been activated with a mixture of
triphenylphosphine (Ph3P) and 2,2P-dipyridyl disul¢de (PyS)2 in the
presence of 4-(N,N-dimethylamino)pyridine (DMAP) [16]. Shortly,
the reaction mixture containing 0.5 Wmol of the N-cetyl-N,N,N-tri-
methylammonium salt of the oligonucleotide, 15 Wmol of Ph3P,
15 Wmol of (PyS)2 and 30 Wmol of DMAP in 0.1 ml dimethylforma-
mide (DMFA) was incubated for 12 min at room temperature. Then
30 Wmol of 9-(aminomethyl)anthracene in 20 Wl of DMFA was added
and the solution was incubated for 1 h at 25‡C. The anthracene de-
rivative of oligodeoxyribonucleotide (1) was precipitated with 2%
LiClO4 in acetone. Puri¢cation of the anthracene oligonucleotide de-
rivative (1) was performed by reversed-phase HPLC using a LiChro-
sorb RP-18, 10 Wm (Merck, FRG), 4.6U250 mm column, a Waters
600E chromatograph and a Waters 484 tunable absorbance detector
(USA). A linear gradient (2 ml/min) from 0 to 30% of acetonitrile in
0.05 M LiClO4 pH 7.5 was used. Lithium salt of anthracene oligonu-
cleotide derivatives (1) (0.2^0.5 Wmol) was dissolved in 30 Wl of H2O
and 25 Wmol of the compound 2 in 10 Wl DMFA was added. The
reaction mixture was incubated for 2 h at 50‡C and oligonucleotide
conjugate 3 (further in the text named as 2B-R) was precipitated with
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2% LiClO4 in acetone and puri¢ed by reversed-phase HPLC in the
same conditions.
2.2. Hydrolysis of tRNAPhe by oligonucleotide conjugate 2B-R
Reaction mixtures (10 Wl) contained 50 mM imidazole bu¡er, pH
7.0, 200 mM KCl, 1 mM EDTA, 100 Wg/ml tRNA carrier (total
tRNA from Escherichia coli), 5U1037 M 3P-[32P]tRNAPhe and oligo-
nucleotide conjugate 2B-R at concentrations ranging from 5U1037 M
to 7U1034 M as indicated in the legends to the ¢gures. The reaction
mixtures were incubated at 37‡C. The reactions were quenched by
precipitation of tRNA with 150 ml of 2% lithium perchlorate solution
in acetone. RNA was collected by centrifugation and dissolved in the
loading bu¡er (6 M urea, 0.025% bromophenol blue, 0.025% xylene
cyanol). The cleavage products were analyzed by electrophoresis in
12% polyacrylamide^8 M urea gel. To identify the cleavage sites,
imidazole ladder and partial T1 RNase digest of the tRNA were
run in parallel with the cleavage products. To get quantitative data,
the gels were dried, radioactive bands were cut out of the gel and their
radioactivity was determined by Cherenkov’s counting.
2.3. Inhibition of the tRNAPhe cleavage by oligonucleotides
The following oligonucleotides were used as inhibitors:
In the competition experiments, standard reaction mixture (volume
10 Wl, containing 50 mM imidazole bu¡er, pH 7.0, 200 mM KCl,
1 mM EDTA, 100 Wg/ml tRNA carrier, 5U1037 M 3P-[32P]tRNAPhe)
lacking 2B-R and supplemented with one of the oligonucleotide com-
petitors at a concentration of 5U1035 M was incubated for 10 min at
37‡C. After the incubation, the oligonucleotide conjugate 2B-R was
added up to a concentration of 5U1036 M and the reaction was
incubated at 37‡C for di¡erent times (from 30 min to 2 h). The
reaction was quenched and analyzed as described above.
3. Results and discussion
The synthesis of oligonucleotide conjugate is presented in
Scheme 1. Anthracene derivative of oligonucleotide was syn-
thesized by condensation of activated 5P-phosphate of oligo-
nucleotide with 9-(aminomethyl)anthracene. Ph3P and 2,2P-di-
pyridyl-disul¢de in the presence of DMAP activate exclusively
the terminal phosphate group of oligonucleotide without in-
teracting with internucleotide phosphate groups and hetero-
cyclic bases [16]. The derivatized oligonucleotide is eluted
from the HPLC columns after the parent oligonucleotide
(The conditions of HPLC isolation are indicated in Section
2). In the course of anion-exchange chromatography (Polisil-
SA 15 Wm, 2.5U30 mm column with a linear gradient of
K2HPO4/KH2PO4, pH 7.0; 0^0.8 M, £ow rate = 50 Wl/min
was employed) the oligonucleotide derivative is eluted as com-
pound having one negative charge less than the parent oligo-
nucleotide, in accordance with the expected behavior of the
structure in which the oligonucleotide and anthracene residue
are connected by a phosphoramide bond. The UV absorption
spectra of the conjugate have a Vmax at 388 nm, characteristic
of the connected anthracene residue [17]. Incubation of 1 with
2 yielded the conjugate, the cycloaddition product 3 (2B-R).
The isolated compound was homogeneous according to the
Scheme 1. Conjugation of the bis-imidazole construct to the oligonucleotide.
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data of anion-exchange and reversed-phase chromatography.
The yield was 85^90%.
Earlier we have shown, that oligonucleotides conjugated to
constructs with imidazole groups can bind to complementary
sequences within the T-loop of tRNAPhe and cleave the mol-
ecule at the target sequence CA [12]. However detailed inves-
tigation of the process has shown that the conjugates were
unstable in the experimental conditions. Hydrolysis of the
phosphoramide bond connecting the catalytic group and the
oligonucleotide occurred, apparently due to intramolecular
catalysis by the imidazoles juxtaposed to the linkage. As a
result, e⁄ciency of the RNA cleavage by the conjugates was
decreased and varied in di¡erent reaction conditions. In the
conjugate described in the present paper, a bulky rigid spacer
structure separates the phosphoramide bond and the catalytic
group and interferes with the intramolecular reaction.
Oligonucleotide 2B is complementary to sequence 44^60 in
the tRNAPhe including the variable loop and part of the T-
arm of the tRNA (Fig. 1). Earlier it was found, that 2B can
bind to the tRNA in physiological conditions [18]. The RNA
cleaving group (compound 2) conjugated to the 5P-terminal
phosphate of the oligonucleotide via a linker can reach the
sequence CACA that is particularly susceptible to cleavage by
small ribonuclease mimics [8]. Fig. 2 displays an autoradio-
graph of the cleavage patterns of the 3P-end-labeled tRNAPhe
by the oligonucleotide conjugate 2B-R. Spontaneous degrada-
tion of tRNA in these conditions in the absence of the con-
jugate, in the presence of the parent non-modi¢ed oligonu-
cleotide and non-linked small ribonuclease mimic does not
occur (Fig. 2). It is seen, that the major cleavage (V90%)
occurs within the C63^A64 sequence (Figs. 1 and 2). Besides
there appears a few faint cleavages within C61^A62, U8^A9
and C75^C76. The ratios between tRNA cleavage products at
C63^A64 and C61^A62 sequences adjacent to each other are
probably consistent with the sterical availability of A61^C62,
A63^C64 phosphodiester bonds towards hydrolysis by 2B-R.
Sequences U8^A9 and C75^A76 are highly sensitive to the
cleavage by RNase A and imidazole containing constructs
[5,9]. Therefore, the faint cleavage within these sites might
result either from sequence speci¢c cleavage (due to the length
of the reactive part of 2B-R) or tRNA spontaneous cleavage
in heteroduplex with the oligonucleotide conjugate. RNA is
cleaved by conjugate 2B-R very rapidly. At conjugate concen-
tration 10 WM, providing e⁄ciency of the complex formation,
the RNA is cleaved predominantly at the C63^A64 bond with
a hal£ife time of approximately 30 min, and at [2B-R] = 50
WM the tRNA hal£ife time is measured by minutes (Fig. 2).
To prove the a⁄nity character of the cleavage, the reaction
was performed in the presence of oligonucleotide inhibitors
(Fig. 3). As expected, the reaction was suppressed by the
oligonucleotides complementary to the target sequence (2A
Fig. 1. Yeast tRNAPhe : cloverleaf structure with indicated target
sites for oligonucleotides 1B, 1A, 1D, 2A, 2B. Sequences of the oli-
gonucleotides are presented at the bottom.
Fig. 2. Cleavage of 3P-end-labeled yeast tRNAPhe with oligonucleo-
tide conjugate 2B-R. Autoradiograph of 12% polyacrylamide^8 M
urea gel after analysis the products of tRNAPhe cleavage with 2B-R.
Cleavage conditions: 37‡C, 50 mM imidazole, pH 7.0, 200 mM
KCI, 0.1 mM EDTA, 100 Wg/ml of tRNA carrier, 5U1037 M 3
0
-
[32P]tRNAPhe. Lanes L and T1 represent the imidazole ladder and
partial tRNAPhe digestion with RNase T1; lane C, incubation of
tRNAPhe without oligonucleotides. Lanes ON2B, incubation of
tRNAPhe in the presence of oligonucleotide 2B; lanes Conjugate, in-
cubation of tRNAPhe in the presence of oligonucleotide conjugate
2B-R and lanes ON2B+R, tRNAPhe incubated in the presence of
equimolar mixture of oligonucleotide 2B and compound 2 (see
Scheme 1). Reaction time and oligonucleotide concentrations are in-
dicated on the top of the gel. The cleavage positions are indicated
on the right.
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and 2B) and by oligonucleotides forming duplex with the se-
quence to be cleaved (1A and 1D). Oligonucleotide 1B forms
a duplex with the sequence adjacent to the linkage C63^A64
to be cleaved and partially suppress the reaction, apparently
because the adjacent duplex reduced the £exibility of the in-
ternucleotide linkage, needed for the transesteri¢cation pro-
cess.
Sequence speci¢c hydrolysis of RNA was achieved using
oligonucleotides conjugated to groups with chelated metal
ions (for reviews see [4,5]). The most promising results have
been obtained with terpyridyl^Cu(II) [19], the iminodiacetate^
Lu(II) complex [20,21] and terpyridine-derived europium com-
plexes [22,23]. In the last case cleavage e⁄ciency compatible
with potential biological applications was observed. However,
possibilities of using the conjugates with chelated metal ions
are limited by relative instability of the complexes in in vivo
conditions. Attempts have been made to design RNA cleaving
oligonucleotide conjugates with small organic RNA cleaving
groups. Cleaving of RNA was shown to occur in complexes of
RNA with complementary oligonucleotides bearing an ethyl-
enediamine residue [24^27], alternating amino acids with basic
and hydrophobic side chains [28] and constructs with imida-
zole groups [10^12,29,30].
The oligonucleotide conjugate described in the present pa-
per demonstrates high cleavage e⁄ciency. In optimal condi-
tions, the hal£ife time of the RNA complexed to conjugate
2BR is measured by minutes. This e⁄ciency is achieved by
design of the structure of the RNA cleaving group and by
choice of the target RNA sequence that is particularly sensi-
tive to RNase mimics. Further investigation of factors a¡ect-
ing the susceptibility of phosphodiester bonds to hydrolyzing
agents and optimization of structure of the catalytic group
will lead to design of e⁄cient RNA-cleaving oligonucleotide
conjugates that will ¢nd applications in development of anti-
sense therapeutics.
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Fig. 3. E¡ect of oligonucleotide competitors on the cleavage of 3P-
end-labeled yeast tRNAPhe with oligonucleotide conjugate 2B-R.
Cleavage conditions were: 37‡C, 2 h, 50 mM imidazole, pH 7.0,
200 mM KCI, 1 mM EDTA, 100 Wg/ml tRNA carrier, 5U1037 M
3P-[32P]tRNAPhe ; the concentration of 2B-R was 10 WM, concentra-
tions of oligonucleotides 2A, 2B, 1B, 1A, 1D and S (scrambled oli-
gonucleotide) were 100 WM. R ^ incubation of tRNA in the pres-
ence of compound 2, ON* ^ incubation of tRNAPhe in the presence
of 100 WM of one of the oligonucleotides 2A, 2B, 1B, 1A, 1D or S.
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